CORE TECHNOLOGIES

Core Technologies

These three core technologies are characterized by unique targeting protein delivery, high iPS stem cells conversion rate and in vivo iPS stem cells conversion, which could not only convert iPS stem cells efficiently in vitro, but also combining with three core technologies as described above, could deliver cell reprogramming proteinsto cell nucleus of diseased tissue in animals, then these delivered proteins start in situ cell reprogramming in disease cells/tissue, finally these newly generated transient stem cells could differentiate into normal cells required by the tissue in the microenvironment.

  • Clinical Medical Research
  • Medical Research
  • Non-Medical

U.S. Address:

440 Burroughs Street, Ste 448;Detroit, MI 48202, USA

001 618 201 4310

qurgen@qurgen.com

Asia Pacific Headquarters:
Fuent Biotechnology Co. Ltd (Shanghai)

12A, Junyao International Plaza, No. 789, Zhaojiabang Road, Shanghai

021-54970007

fuent@qurgen.com

Company's E-mail:

fuent@qurgen.com